Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel D Shapiro

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
European Urology Oncology|June 2, 2023
Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610Daniel D Shapiro, Jose A Karam, Viraj A Master, et al.
BJUI Compass|April 27, 2022
Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomyDaniel D Shapiro, John W Davis, Wendell H Williams, et al.
Abdominal Radiology (New York)|June 20, 2022
Differentiation of benign from malignant solid renal lesions with MRI-based radiomics and machine learningRuben Ngnitewe Massa'a, Elizabeth M Stoeckl, Meghan G Lubner, et al.
Urology|September 20, 2023
Impact of Agent Orange Exposure on Non-muscle Invasive Bladder Cancer OutcomesTaylor Penn, Tudor Borza, Jinn-Ing Liou, et al.
Cancers|May 13, 2023
Understanding the Tumor Immune Microenvironment in Renal Cell CarcinomaDaniel D Shapiro, Brendan Dolan, Israa A Laklouk, et al.
European Urology|May 6, 2023
Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6Daniel D Shapiro, Jose A Karam, Viraj A Master, et al.
Cancers|June 26, 2025
Statins Are Not Associated with Improved Bladder Cancer Outcomes in Patients with Early-Stage Bladder Cancer Treated with BCG ImmunotherapyEstelle Ndukwe, Paz Lotan, Michael Risk, et al.
Clinical Genitourinary Cancer|September 6, 2024
Paraneoplastic Syndrome Prevalence and Survival in Racially-Diverse Cohort With Renal Cell CarcinomaEdouard H Nicaise, Benjamin N Schmeusser, Gregory Palmateer, et al.
Cancers|November 9, 2024
Paraneoplastic Resolution Holds Prognostic Utility in Patients with Metastatic Renal Cell CarcinomaGregory Palmateer, Edouard H Nicaise, Taylor Goodstein, et al.
BJU International|May 2, 2020
Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillanceDaniel D Shapiro, Justin R Gregg, Amy H Lim, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
European Urology Oncology|June 2, 2023
Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610Daniel D Shapiro, Jose A Karam, Viraj A Master, et al.
BJUI Compass|April 27, 2022
Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomyDaniel D Shapiro, John W Davis, Wendell H Williams, et al.
Abdominal Radiology (New York)|June 20, 2022
Differentiation of benign from malignant solid renal lesions with MRI-based radiomics and machine learningRuben Ngnitewe Massa'a, Elizabeth M Stoeckl, Meghan G Lubner, et al.
Urology|September 20, 2023
Impact of Agent Orange Exposure on Non-muscle Invasive Bladder Cancer OutcomesTaylor Penn, Tudor Borza, Jinn-Ing Liou, et al.
Cancers|May 13, 2023
Understanding the Tumor Immune Microenvironment in Renal Cell CarcinomaDaniel D Shapiro, Brendan Dolan, Israa A Laklouk, et al.
European Urology|May 6, 2023
Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6Daniel D Shapiro, Jose A Karam, Viraj A Master, et al.
Cancers|June 26, 2025
Statins Are Not Associated with Improved Bladder Cancer Outcomes in Patients with Early-Stage Bladder Cancer Treated with BCG ImmunotherapyEstelle Ndukwe, Paz Lotan, Michael Risk, et al.
Clinical Genitourinary Cancer|September 6, 2024
Paraneoplastic Syndrome Prevalence and Survival in Racially-Diverse Cohort With Renal Cell CarcinomaEdouard H Nicaise, Benjamin N Schmeusser, Gregory Palmateer, et al.
Cancers|November 9, 2024
Paraneoplastic Resolution Holds Prognostic Utility in Patients with Metastatic Renal Cell CarcinomaGregory Palmateer, Edouard H Nicaise, Taylor Goodstein, et al.
BJU International|May 2, 2020
Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillanceDaniel D Shapiro, Justin R Gregg, Amy H Lim, et al.
Pageof 7